Literatur
-
1
Behr J, Maier K, Degenkolb B. et al .
Antioxidative und clinical effects of high-dose
N-acetylcysteine in fibrosing alveolitis. Adjunctive therapy to
maintenance immunosuppression.
Am J Respir Crit Care Med.
1997;
156
1897-1901
-
2
Bridgeman M ME, Marsden M, Selby C. et al .
Effect of N-acetylcysteine on the concentrations
of thiols in plasma, bronchoalveolar lavage fluid, and lung tissue.
Thorax.
1994;
49
670-675
-
3
British Thoracic Society Research
Committee .
Oral N-Acetylcysteine and exacerbation rates
in patients with chronic bronchitis and severe airways obstruction.
Thorax.
1985;
40
832-835
-
4
Holdiness M R.
Clinical
pharmacokinetics of N-acetylcysteine.
Clin Pharmacokinet.
1991;
20
123-134
-
5
Pauwels R A, Buist A S, Calverley P MA. et al .
Global Strategy for the
Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary
Disease.
Am J Respir Crit Care Med.
2001;
163
1256-1276
-
6
Prescott L F, Donovan J W, Jarvie D R. et al .
The disposition and kinetics
of intravenous N-acetylcysteine in patients with paracetamol overdosage.
Eur
J Clin Pharmacol.
1989;
37
501-506
-
7
Rasmussen J B, Glennow C.
Reduction in days of
illness after long term treatment with N-acetyl cysteine controlled-release tablets
in patients with chronic bronchitis.
Eur J Respir Dis.
1988;
1
351-355
-
8
Worth H, Buhl R, Cegla U. et
al .
Leitlinie der Deutschen Atemwegsliga und der Deutschen
Gesellschaft für Pneumologie zur Diagnostik und Therapie
von Patienten mit chronisch obstruktiver Bronchitis und Lungenemphysem
(COPD).
Pneumologie.
2002;
56
1-35
Autor
Prof. Dr. med. A. Gillissen
Robert Koch-Klinik, Städt. Klinikum „St.
Georg“
Nikolai-Rumjanzew-Straße 100
04207 Leipzig
